Sir -In this issue, McPherson et al. (1987) report a case control study of oral contraceptive (OC) use and breast cancer. They concentrated on the 351 pairs of women under 45 years at diagnosis and found a significantly elevated relative risk (2.6) associated with more than 4 years of use before the first full term pregnancy. There was, however, no increase in risk in nulliparous women less than 45 or those who had used OC before the age of 25. The authors evaluate their data critically but a number of points appear worthy of further comment. As they emphasise their results are at variance with the large study of Stadel et al. (1985) as well as the five cohort studies (Lipnick et al., 1986) (1980) (1981) (1982) (1983) (1984) showed a larger number with arthritis, skin or musculo-skeletal disorders than the first part. Although the excess of long term use of oral contraceptives is not confined to cases matched with these controls it does account for a major proportion. Oral contraceptives are known to affect some skin diseases adversely (RCGP, 1974) , former use in controls may therefore be less. Conversely rheumatoid arthritis, the major component of 'arthritis/musculo-skeletal disorder' is known to derive benefit from OC use (Wingrave et al., 1978) which may be greater in those subjects.
The least plausible conclusion of the study is the adverse effect of ethinyl oestradiol. Although the peak plasma level achieved is lower than in those taking mestranol the area under the concentration/time curve is virtually the same for mestranol and ethinyl oestradiol (Goldzieher et al., 1980) , and as they are interconverted it is hard to imagine a differential effect.
The authors hypothesise a latent effect of at least 10 years between long term early OC exposure and an increased risk of breast cancer diagnosis based on a theoretical model (McPherson et al., 1986 ). It 
